ArticleCase reports in gastroenterology
Pseudomelanosis Duodeni after Intravenous Iron Supplementation in a Patient with Multiple Comorbidities: A Case Report.
Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pseudomelanosis duodeni (PD) is a rare condition characterized by multiple pigmented speckles in the duodenum. It is typically seen in adults and has been associated with chronic kidney disease, hypertension, iron deficiency anemia, diabetes mellitus, and the use of medications like oral iron, hydralazine, furosemide, and hydrochlorothiazide. While oral iron is common, only one documented PD has been associated with intravenous (IV) iron supplementation. Case Presentation: A 69-year-old female with multiple comorbidities, including stage 4 chronic kidney disease and hypertension, presented with persistent nausea and vomiting. An esophagogastroduodenoscopy (EGD) revealed diffuse, dark speckling throughout the duodenal mucosa. Biopsies confirmed PD through Perl Prussian blue and Fontana-Masson staining, which detected iron in black/brown pigmentations within macrophages. The patient received a 5-week course of weekly intravenous iron supplementation 6 months before presentation. Previous EGD 7 and 5 years earlier showed no evidence of PD despite the patient being on sulfur-containing antihypertensive medications. This case suggests a likely interplay between IV iron and sulfur-containing medications in PD development. Conclusion: While PD has been associated with multiple comorbidities and certain medications, the causal mechanism remains unclear. PD likely entails defective iron transport and iron sulfide accumulation within duodenal macrophages. This case highlights the potential role of IV iron supplementation in PD development, even in the absence of oral iron intake. PD is regarded as a benign condition with no specific guidelines for treatment or follow-up, but a biopsy is crucial to rule out other differential diagnoses and avoid unwanted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.